Connection

Giuseppe Curigliano to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Giuseppe Curigliano has written about Antibodies, Monoclonal, Humanized.
Giuseppe Curigliano
Connection Strength
0.101
Antibodies, Monoclonal, Humanized
  1. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019 03; 20(3):371-382.
    View in: PubMed
    Score: 0.041
  2. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018 03; 19(3):323-336.
    View in: PubMed
    Score: 0.038
  3. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. Eur J Cancer. 2020 08; 135:62-65.
    View in: PubMed
    Score: 0.011
  4. Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. Eur J Cancer. 2019 11; 122:22-41.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.